MedX Health Corp said it recently convened medical advisory boards of leading dermatologists across Canada and the US to explore clinical application opportunities for its image capture technology SIAscopy and patient management system DermSecure.
The company said summarized findings from the two boards will help validate the technological uses and benefits of SIAscopy in clinical practice, particularly as a triage tool for the assessment of suspicious moles and lesions.
And the boards’ recommendations will be compiled and published in the coming months through separate publications pertaining to the Canadian and US markets.
READ: MedX says its teledermatology screening platform to be distributed by Al Zahrawi in the United Arab Emirates
“This technology has the potential to save many lives as an effective triage tool,” said Dr. Daniel Siegel, chair of the US-based medical advisory board, in a statement. “Scanning more at-risk patients in easy to access locations will provide greater early detection of cancerous and precancerous lesions, providing better patient outcomes while lowering overall healthcare costs.”
Dr. Siegel said MedX’s DermSecure platform offers a very complete teledermatology solution – with its unique imaging technology that can provide dermatologists with high-resolution images of pigmented lesions for evaluation along with multispectral images that enhance diagnostic accuracy.
“Until now, most teledermatology offerings could not provide high-quality images of potentially deadly melanomas to dermatologists for assessment. This is truly an industry gamechanger,” he said.
Dr. Charles Lynde, chair of the Canadian-based board, added: “This technology shows tremendous promise for positively impacting patient care, particularly as a tool for patients and clinicians seeking second opinions. Because of the quality of SIAscopy’s high-resolution images, we’re also interested in its potential for assessing a wide range of additional skin conditions.”
Meanwhile, MedX said a similar medical advisory board consultation process is also underway in the UK, which will be shortly followed by the formation of a European-based board.
MedX’s SIAscopy is the only technology on the market that captures five high-resolution images, including four spectrophotometric images 2 millimeters (mm) below the skin’s surface, enabling dermatological assessment of suspicious moles and lesions in a pain-free, non-invasive manner.
Combined with MedX’s DermSecure Screening Platform – its secure, cloud-based patient management system – these high-resolution images are transmitted safely and securely for virtual dermatological assessment by a certified dermatologist within just 72 hours, compared to a wait time of five months to one year for traditional dermatological assessment.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham